Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vesleteplirsen · SRP-5051

Oligonucleotide (Antisense oligonucleotide) · Acts on dystrophin (DMD) pre-mRNA (DMD) · developed by Sarepta Therapeutics

Phase 2 Most advanced trial (none active)
SRPT Developer
2 Registered trials

What is Vesleteplirsen?

Vesleteplirsen (SRP-5051) is an intravenously administered oligonucleotide. It is studied in Duchenne muscular dystrophy, a disease of the DMD gene's dystrophin protein.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SRP-5051
Drug type
Oligonucleotide (Antisense oligonucleotide)
Targets
dystrophin (DMD) pre-mRNA (DMD)
Mechanism
Acts on dystrophin (DMD) pre-mRNA (DMD)
Pathways
exon skipping
Therapy area
Neurology
Developer
Sarepta Therapeutics, Inc. (SRPT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
F6U7EZ3N1Q

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04004065 Phase 2 Duchenne Muscular Dystrophy Terminated SRPT
NCT03675126 Phase 1/2 Muscular Dystrophy, Duchenne Terminated SRPT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Duchenne Muscular DystrophyMuscular Dystrophy, Duchenne

Other drugs acting on DMD

More from Sarepta Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.

Follow SRPT, the company behind Vesleteplirsen

See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SRPT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.